Moleculin Biotech Inc. (MBRX)
NASDAQ: MBRX
· Real-Time Price · USD
0.96
-0.03 (-3.37%)
At close: May 20, 2025, 3:58 PM
0.98
1.55%
Pre-market: May 21, 2025, 06:49 AM EDT
-3.37% (1D)
| Bid | 0.93 |
| Market Cap | 13.63M |
| Revenue (ttm) | 63K |
| Net Income (ttm) | -23.23M |
| EPS (ttm) | -6.32 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.57 |
| Analyst | Buy |
| Ask | 0.98 |
| Volume | 241,423 |
| Avg. Volume (20D) | 1,463,981 |
| Open | 1.00 |
| Previous Close | 0.99 |
| Day's Range | 0.93 - 1.00 |
| 52-Week Range | 0.40 - 5.15 |
| Beta | 1.64 |
About MBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+202.38%
Moleculin Biotech shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago
+14.72%
Moleculin Biotech shares are trading higher after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model which demonstrated significant activity.
